Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Preferred Stock Liabilities (2021 - 2022)

Coeptis Therapeutics Holdings (COEP) has 2 years of Preferred Stock Liabilities data on record, last reported at $33.3 million in Q3 2022.

  • For Q3 2022, Preferred Stock Liabilities fell 56.09% year-over-year to $33.3 million; the TTM value through Sep 2022 reached $33.3 million, down 56.09%, while the annual FY2021 figure was $75.8 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $33.3 million in Q3 2022 per COEP's latest filing, up from $33.0 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $75.8 million in Q4 2021 and bottomed at $33.0 million in Q2 2022.